References
Pharmacokinetics of Intravenous Vitamin C and Cancer Cell Mechanisms:
- Padayatty SJ, Sun H, Wang Y, et al. Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use. Annals of Internal Medicine. 2004;140(7):533–537. doi:10.7326/0003-4819-140-7-200404060-00010.
- Chen Q, Espey MG, Krishna MC, et al. Pharmacologic Ascorbic Acid Concentrations Selectively Kill Cancer Cells: Action as a Pro-Drug to Deliver Hydrogen Peroxide to Tissues. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(38):13604–13609. doi:10.1073/pnas.0506390102.
Clinical Studies of High-Dose Intravenous Vitamin C in Patients With Cancer:
- Hoffer LJ, Levine M, Assouline S, et al. Phase I Clinical Trial of I.V. Ascorbic Acid in Advanced Malignancy. Annals of Oncology. 2008;19(11):1969–1974. doi:10.1093/annonc/mdn377.
- Stephenson CM, Levin RD, Spector T, Lis CG. Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of High-Dose Intravenous Ascorbic Acid in Patients with Advanced Cancer. Cancer Chemotherapy and Pharmacology. 2013;72(1):139–146. doi:10.1007/s00280-013-2179-9.
- Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy. Science Translational Medicine. 2014;6(222):222ra18. doi:10.1126/scitranslmed.3007154.
Quality of Life, Fatigue and Supportive Care:
- Yeom CH, Jung GC, Song KJ. Changes of Terminal Cancer Patients’ Health-Related Quality of Life after High Dose Vitamin C Administration. Journal of Korean Medical Science. 2007;22(1):7–11. doi:10.3346/jkms.2007.22.1.7.
- Fritz H, Flower G, Weeks L, et al. Intravenous Vitamin C and Cancer: A Systematic Review. Integrative Cancer Therapies. 2014;13(4):280–300. doi:10.1177/1534735414534463.
Safety Screening and Risk Monitoring for High-Dose Intravenous Vitamin C:
- National Cancer Institute (NCI). Intravenous Vitamin C (PDQ®) — Health Professional Version. National Cancer Institute.
- Lawton JM, Conway LT, Crosson JT, Smith CL, Abraham PA. Acute Oxalate Nephropathy After Massive Ascorbic Acid Administration. Archives of Internal Medicine. 1985;145(5):950–951. doi:10.1001/archinte.1985.00360050220044.
- Lo YH, Mok KL. High Dose Vitamin C Induced Methemoglobinemia and Hemolytic Anemia in Glucose-6-Phosphate Dehydrogenase Deficiency. American Journal of Emergency Medicine. 2020;38(11):2488.e3–2488.e5. doi:10.1016/j.ajem.2020.05.099.
- Kahn SA, Lentz CW. Fictitious Hyperglycemia: Point-of-Care Glucose Measurement Is Inaccurate During High-Dose Vitamin C Infusion for Burn Shock Resuscitation. Journal of Burn Care & Research. 2015;36(2):e67–e71. doi:10.1097/BCR.0000000000000141.
References
Pharmacokinetics of Intravenous Vitamin C and Cancer Cell Mechanisms:
- Padayatty SJ, Sun H, Wang Y, et al. Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use. Annals of Internal Medicine. 2004;140(7):533–537. doi:10.7326/0003-4819-140-7-200404060-00010.
- Chen Q, Espey MG, Krishna MC, et al. Pharmacologic Ascorbic Acid Concentrations Selectively Kill Cancer Cells: Action as a Pro-Drug to Deliver Hydrogen Peroxide to Tissues. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(38):13604–13609. doi:10.1073/pnas.0506390102.
Clinical Studies of High-Dose Intravenous Vitamin C in Patients With Cancer:
- Hoffer LJ, Levine M, Assouline S, et al. Phase I Clinical Trial of I.V. Ascorbic Acid in Advanced Malignancy. Annals of Oncology. 2008;19(11):1969–1974. doi:10.1093/annonc/mdn377.
- Stephenson CM, Levin RD, Spector T, Lis CG. Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of High-Dose Intravenous Ascorbic Acid in Patients with Advanced Cancer. Cancer Chemotherapy and Pharmacology. 2013;72(1):139–146. doi:10.1007/s00280-013-2179-9.
- Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy. Science Translational Medicine. 2014;6(222):222ra18. doi:10.1126/scitranslmed.3007154.
Quality of Life, Fatigue and Supportive Care:
- Yeom CH, Jung GC, Song KJ. Changes of Terminal Cancer Patients’ Health-Related Quality of Life after High Dose Vitamin C Administration. Journal of Korean Medical Science. 2007;22(1):7–11. doi:10.3346/jkms.2007.22.1.7.
- Fritz H, Flower G, Weeks L, et al. Intravenous Vitamin C and Cancer: A Systematic Review. Integrative Cancer Therapies. 2014;13(4):280–300. doi:10.1177/1534735414534463.
Safety Screening and Risk Monitoring for High-Dose Intravenous Vitamin C:
- National Cancer Institute (NCI). Intravenous Vitamin C (PDQ®) — Health Professional Version. National Cancer Institute.
- Lawton JM, Conway LT, Crosson JT, Smith CL, Abraham PA. Acute Oxalate Nephropathy After Massive Ascorbic Acid Administration. Archives of Internal Medicine. 1985;145(5):950–951. doi:10.1001/archinte.1985.00360050220044.
- Lo YH, Mok KL. High Dose Vitamin C Induced Methemoglobinemia and Hemolytic Anemia in Glucose-6-Phosphate Dehydrogenase Deficiency. American Journal of Emergency Medicine. 2020;38(11):2488.e3–2488.e5. doi:10.1016/j.ajem.2020.05.099.
- Kahn SA, Lentz CW. Fictitious Hyperglycemia: Point-of-Care Glucose Measurement Is Inaccurate During High-Dose Vitamin C Infusion for Burn Shock Resuscitation. Journal of Burn Care & Research. 2015;36(2):e67–e71. doi:10.1097/BCR.0000000000000141.